Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection.

摘要: One potential complication of systemic herpes simplex virus (HSV) vaccination is that subsequent ocular infection may lead to increased immunogenic corneal scarring. Therefore, V52, a genetically engineered vaccinia expresses the HSV-1 glycoprotein gD, was tested for safety and protection against challenge with stromal-disease-producing strain (McKrae) HSV-1. To maximize immune response, rabbits were vaccinated by series inoculations. V52-vaccinated developed significant neutralizing antibody titers; however, they not as high those induced live McKrae. month after final vaccination, all challenged ocularly. Eyes monitored 35 days epithelial keratitis, stromal iritis. In no case or iritis significantly exacerbated vaccination. The gD V52 recombinant vaccine provided keratitis (P = 0.02) long-term scarring 0.04). There reduction in incidence trigeminal ganglionic latency greater than 0.05). Thus, our results indicate probably safe regard scarring, provide small amount infection. less reported mice guinea pigs. This suggests levels (and humans), vaccines have elicit more vigorous response produced normal